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Background: Approximately one third of women diagnosed with ovarian cancer is 70 years or older. Information
on the treatment reality of these elderly patients is limited.
Methods: 275 patients with primary epithelial ovarian cancer FIGO stage II-IV undergoing cytoreductive surgery
and platinum-based chemotherapy were prospectively included in this European multicenter study. Patients <70
and ≥70 years were compared regarding clinicopathological variables and prognosis.
Results: Median age was 58 years (18–85); 47 patients (17.1%) were 70 years or older. The postoperative 60-day
-mortality rate was 2.1% for elderly and 0.4% for younger patients (p < 0.001). Elderly patients were less likely to
receive optimal therapy (no residual disease after surgery and platinum combination chemotherapy) compared to
patients <70 years (40.4% vs. 70.1%, p < 0.001) and their outcome was less favorable regarding median PFS (12 vs.
20 months, p = 0.022) and OS (30 vs. 64 months, p < 0.001). However, in multivariate analysis age itself was not a
prognostic factor for PFS while the ECOG performance status had prognostic significance in elderly patients.
Conclusions: Elderly patients with ovarian cancer are often treated less radically. Their outcome is impaired despite
no consistent prognostic effect of age itself. Biological age and functional status should be considered before
individualized treatment plans are defined.
Keywords: Ovarian cancer, Prognosis, Elderly, Surgery, Chemotherapy, Performance statusBackground
Women aged 65 and above represent the fastest-growing
population segment with consecutively rising incidence of
malignancies [1]. Median age at first diagnosis of ovarian
cancer is currently 63 years with approximately one third
aged 70 or older [2]. With the progressive demographic
changes the percentage of elderly patients will further rise
and gynecologic oncologists will have to focus on these
patients and their specific needs. Current evidence on the
treatment of ovarian cancer in this patient cohort is
scarce. Prospective phase III trials concentrating on* Correspondence: s.mahner@uke.de
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reproduction in any medium, provided the orovarian cancer therapy usually reveal an underrepresenta-
tion of elderly patients as physicians seem to hesitate to
enrol these patients even if it is possible according to the
study protocol (e.g. AGO OVAR-3 trial with only 13% of
patients ≥ 70 years) [3].
Irrespective of age, ovarian cancer is still regarded the
most lethal gynecological malignancy with a median over-
all survival of approximately 44 months [4]. However,
even in advanced tumor stage (FIGO [International Feder-
ation of Gynecology and Obstetrics] stage ≥ IIB) the
intention of treatment is still curative achieving a rate of
approximately 20% of patients without relapse after opti-
mal primary treatment [4]. Optimal treatment thereby
consists of the combination of radical cytoreductive sur-
gery (resection of all visible tumor) plus platinum-basedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cant morbidity [4].
In contrast to the well-established prognostic factors
postoperative residual tumor load, FIGO stage at first
diagnosis and lymph node involvement the role of age it-
self for ovarian cancer patients has been controversially
discussed in the past. While several studies found higher
age to be associated with poor survival [5-7], it could not
be proven as an independent prognostic factor in a recent
large, retrospective cohort study from Denmark [8]. The
reason might be that the impact of age is strongly
influenced by other factors such as co-morbidities and
suboptimal therapeutic management [8].
To further understand the role of age for outcome and
treatment of ovarian cancer we analyzed the cohort of pro-
spectively enrolled patients from the Sixth Framework
Programme (FP6) EU project “OVCAD – Diagnosis of a Si-
lent Killer” with focus on age. The project was implemented
in 2005 by 5 large European gynecologic cancer centers to
identify and verify clinical and molecular prognostic factors
for ovarian cancer. The present analysis investigates the
prognostic value of age itself as well as possible confounders
impairing the prognosis of elderly patients and further elab-




Patients with advanced epithelial ovarian cancer FIGO
II-IV were prospectively enrolled into the OVCAD project
between February 2005 and December 2008 by five European
Gynecological Cancer Centers (Charité University Medical
Center Berlin, Germany; University Hospitals Leuven,
Belgium; University Medical Center Hamburg-Eppendorf,
Germany; Medical University of Vienna, Austria; and
Innsbruck Medical University, Austria). Data from other
clinical subprojects of the OVCAD project has recently
been published [9-11].
Patients had to be 18 years or older without evidence
of any other primary tumor affecting prognosis or treat-
ment of ovarian cancer. Patients were eligible for study
entry if radical surgery was performed with the intention
of optimal cytoreduction and platinum-based chemo-
therapy was applied. Systemic treatment could be given
either postoperatively or as neoadjuvant treatment. Pa-
tients were selected for neoadjuvant therapy if they were
not eligible for surgery (e.g. acute thromboembolism) or
initial achievement of complete tumor resection was
judged to be very unlikely with upfront debulking surgery
by the treating gynecologic oncologist in pre-operative
evaluation. Complete surgical staging consisted of total
hysterectomy and bilateral salpingo-oophorectomy, peri-
toneal washings, omentectomy, appendectomy, and resec-
tion of all visible tumor if possible. All histopathologicalreports were re-evaluated for the inclusion criteria after
surgery to guarantee accurate diagnosis and staging. To
measure treatment response, CA-125 levels were assessed
before and after treatment completion and the diagnosis
of disease recurrence or progression was established based
on CA-125 variations (GCIG criteria), imaging studies,
and results of performed biopsies [12]. All patients gave
written informed consent prior to surgery and collection of
any biological samples. The protocol was approved by the
local ethical committees of the different centers and by the
centralized ethical committee of Vienna (www.ovcad.eu).
Clinical data were anonymized and collected in a central-
ized online database (Alcedis GmbH, Germany) solely
accessible by the OVCAD partners.
Statistical analysis
All statistical analyses were conducted using SPSS
software version 20.0 (SPSS Inc., Chicago, IL, USA)
and Stata 11.0 (2009 StataCorp LP, College Station,
Texas, USA). P-values <0.05 were considered statisti-
cally significant.
To evaluate the impact of age on treatment and
prognosis patients were separated in those <70 years
and those ≥70 years as previously proposed [13]. The
subgroups were then compared regarding clinicopath-
ological variables and prognosis by applying Man-
Whitney-U test, chi square test, Fisher’s exact test or
logrank test, as appropriate. Kaplan-Meier method was
used to analyze and illustrate survival. For multivariate
analysis of the prognostic impact of age and performance
status on survival, log-rank tests and Cox regression
models were calculated accounting for multicenter ana-
lysis. These models were applied separately for the whole
patient cohort as well as for elderly patients only.
Results
A total of 275 patients met the inclusion criteria and
were prospectively enrolled into the OVCAD study. Me-
dian age of the total cohort was 58 years (range 18–85)
with 228 patients younger than 70 years (82.9%, median
age 55) and 47 patients aged 70 or older (17.1%, median
age 75). The median follow up was 36 months. Detailed
clinical patient characteristics are provided in Table 1.
Despite the non-randomized setting both patient cohorts
(<70 years vs. ≥70 years) were well balanced in terms of
tumor stage, grading, histological subtype and presence of
ascites or peritoneal carcinomatosis (Table 1). The majority
of patients (71.3%) were diagnosed in FIGO stage IIIC and
17.5% in FIGO stage IV. Classification of stage IV was
mainly because of malignant pleural effusion (35%) or me-
tastases to the liver parenchyma (25%). In the elderly sub-
group FIGO stages were slightly higher (FIGO IIIC 66.0%,
FIGO IV in 23.4%) compared to younger patients, however,
this difference was not statistically significant, p = 0.801.













Median 58 55 75
Range 18-85 18-69 70-85
FIGO stage 0.801c
IIB/C 15 (5.5) 13 (5.7) 2 (4.2)
IIIA/B 16 (5.8) 13 (5.7) 3 (6.4)
IIIC 196 (71.3) 165 (72.4) 31 (66.0)
IV 48 (17.5) 37 (16.2) 11 (23.4)
Nodal status 0.002b
pN0 65 (23.6) 58 (24.4) 7 (14.9)
pN1 143 (52.0) 124 (54.4) 19 (40.4)
Nx 67 (24.4) 46 (20.2) 21 (44.7)
Grading 0.907c
G1 10 (3.6) 9 (4.0) 1 (2.1)
G2 64 (23.4) 54 (23.8) 5 (21.3)
G3 200 (73.0) 164 (72.2) 42 (76.6)
Unknown 1 0 1
Histological subtype 0.700c
Serous 237 (86.2) 194 (85.1) 43 (91.5)
Mucinous 3 (1.1) 3 (1.3) 0 (0.0)
Other* 13 (4.7) 31 (13.6) 4 (8.5)
Presence of ascites 0.964b
None 66 (24.0) 54 (23.7) 12 (25.5)
<500 ml 101 (36.7) 84 (36.8) 17 (36.2)




Yes 186 (67.4) 156 (68.0) 30 (63.8)
No 89 (32.4) 72 (32.0) 17 (36.2)
ECOG 0.047c
0 166 (60.4) 139 (61.0) 27 (57.5)
1 84 (30.6) 73 (32.0) 11 (23.4)
≥2 12 (4.4) 7 (3.1) 5 (10.6)
Unknown 13 (4.7) 9 (4.0) 4 (8.51)
Overview of the clinical characteristics of all included patients with advanced
ovarian cancer (n = 275). A total of 47 elderly patients ≥70 years are opposed
to 228 patients younger than 70 years.
a Man-Whitney-U-test, b Chi2-test, c Fisher’s exact test.
* other = clear cell, endometroid, mixed cell, undifferentiated histology.
FIGO International Federation of Gynecology and Obstetrics.
ECOG Eastern Cooperative Oncology Group performance status.
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age groups with a higher rate of unknown lymph-node sta-
tus (pNx) in elderly patients (44.7% vs. 20.2%, p < 0.001).
Their performance status expressed by the ECOG (Eastern
Cooperative Oncology Group) score was significantly poorercompared to younger patients (ECOG ≥2 in 10.6% vs. 3.1%,
p = 0.047).
In addition, analysis of treatment-related patient charac-
teristics (Table 2) revealed that intraoperative surgical pro-
cedures were comparable except for distinct differences
regarding the frequency of adnectomy (83.0% vs. 96.4%,
p = 0.038), hysterectomy (76.6% vs. 93.0% p = 0.006)
and pelvic (42.6% vs. 75%, p < 0.001) as well as para-
aortic (38.3% vs. 72.8%, p < 0.001) lymphadenectomy in
elderly compared to younger patients, reflected by dif-
ferent nodal status as previously described. There were
no significant differences in terms of upper abdominal
surgery such as bowel resection or splenectomy but
elderly patients underwent interval debulking after
neoadjuvant chemotherapy significantly more frequent
(p = 0.019). Of note, rates of postoperative residual
tumor differed singnificantly (p = 0.029) with higher
rates of suboptimal surgical outcome in elderly pa-
tients (44.7% vs. 28.5%). Intraoperative complication
rates (bladder, liver capsula or spleen lesion, cardiac is-
chemia, large vessel laceration, mass transfusions) were
comparable between both groups (p = 0.532) and the
proportion of patients with an unremarkable postoper-
ative clinical course did also not differ between the
two age groups (p = 0.495). In both groups none of the
patients died within 30 postoperative days (p = 1.00)
while the 60-day mortality rate was slightly but signifi-
cantly higher in elderly patients with 2.13% compared
to 0.44% in patients <70 years (p < 0.001, Table 2).
All included patients received platinum-based chemo-
therapy according to the inclusion criteria but there were
significantly more elderly patients receiving single-agent
platinum instead of a combination regimen (21.3% vs.
2.2% of the younger patients, p < 0.001). Approximately
3/4 of the younger patients experienced clinical response
to primary chemotherapy compared a significantly lower
rate in the elderly cohort (57.4% vs. 78.5%, p = 0.003).
Taken together only 40.4% of the elderly compared to
70.1% of the younger patients received optimal oncologic
treatment as it is considered for the overall patient popula-
tion consisting of complete tumor resection and platinum-
based combination chemotherapy (p < 0.001, Table 2).
Outcome of the age subgroups differed significantly
with median progression-free survival (PFS) of 12 vs. 20
months for elderly patients compared to younger patients
(p = 0.022, Figure 1A, Table 2) and 30 vs. 64 months in
terms of median overall survival (OS) (p < 0.001, Figure 1B,
Table 2). Elderly patients with optimal oncologic manage-
ment had an improved prognosis regarding PFS and OS
compared to elderly patients receiving sub-optimal onco-
logic treatment (median PFS 18 vs. 11 months, p = 0.05;
median OS 31 vs. 20 months, p < 0.001; Figure 2). Of
note, the clinical course of the optimally treated elderly
subgroup approached to that of the cohort of younger
Table 2 Treatment-related patient characteristics
Total (%)
n = 275
Age <70 years (%)
n = 228
Age ≥ 70 years (%)
n = 47
p value for group
differences
Type of surgery 0.019b
Primary cytoreduction 226 (82.2) 193 (84.6) 30 (70.2)
Interval debulking 49 (17.8) 35 (15.4) 14 (29.8)
Surgical interventions
Adnectomy 259 (94.2) 220 (96.4) 39 (83.0) 0.038b
Hysterectomy 248 (90.2) 212 (93.0) 36 (76.6) 0.006b
Omentectomy 255 (92.7) 212 (93.0) 43 (91.5) 0.720b
Pelvic LAE 191 (69.5) 171 (75.0) 20 (42.6) <0.001b
Paraaortic LAE 184 (66.9) 166 (72.8) 18 (38.3) <0.001b
Appendectomy 110 (40.0) 94 (41.2) 16 (34.0) 0.327b
Splenectomy 22 (8.0) 19 (8.3) 3 (6.4) 1.000b
Large bowel resection 104 (37.8) 87 (38.2) 17 (36.2) 0.798b
Small bowel resection 37 (13.4) 27 (11.8) 10 (21.3) 0.084b
Postop. residual tumor 0.029b
Microscopic 189 (68.7) 163 (71.5) 26 (55.3)
Macroscopic 86 (31.3) 65 (28.5) 21 (44.7)
Intraoperative complications 0.532c
Yes 20 (7.2) 16 (7.0) 4 (8.5)
No 247 (89.9) 209 (91.7) 38 (80.9)
Unknown 8 (2.91) 3 (1.3) 5 (10.6)
Postoperative complications 0.495b
Yes 95 (34.6) 82 (36.0) 13 (27.7)
No 172 (62.6) 143 (62.7) 29 (61.7)
Unknown 8 (2.9) 3 (1.3) 5 (10.6)
Mortality rates
30d-mortality rate 0.0 % 0.0 % 0.0 % 1.000d
60d-mortality rate 1.1 % 0.4 % 2.1 % <0.001d
Chemotherapy
courses (median, range) 6 (1–8) 6 (1–8) 6 (2–6) 0.156a
Time to chemo after surgery
(median, range)
34 (5–188) 34 (5–188) 31.5 (9–127) 0.368a
Treatment concept 0.019b
- Neoadjuvant 49 (17.8) 35 (15.4) 14 (29.8)
- Adjuvant 226 (82.2) 193 (84.6) 30 (70.2)
Treatment regimen <0.001c
- Platinum-based combination 260 (94.5) 223 (97.8) 37 (78.7)
- Platinum monotherapy 15 (5.5) 5 (2.2) 10 (21.3)
Response to chemotherapy 205 (74.5) 178 (78.4) 27 (57.4) 0.003b
Optimal oncologic treatment
(no residual tumor + combination
therapy)
<0.001b
Yes 179 (65.1) 160 (70.1) 19 (40.4)
No 96 (34.1) 68 (29.8) 28 (59.6)
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Table 2 Treatment-related patient characteristics (Continued)
Survival (months)
Median PFS 19 20 12 0.022d
Median OS 48 64 30 <0.001d
Detailed overview of surgical procedures, chemotherapy and prognostic aspects. Parameters were separately analyzed for elderly patients ≥70 years and patients
younger than 70 years.
a Man-Whitney-U-test, b Chi2-test, c Fisher’s exact test, d log-rank test.
LAE = lymphadenectomy, PFS = progression free survival, OS = overall survival.
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plied (Figure 2A).
Despite the highly significant differences in prognosis in
univariate analysis, age itself was not an independent
prognostic factor for PFS in multivariate analysis (Table 3).
However, regarding OS age remained highly significant in
the multivariate analysis in the presence of other prognos-
tic factors (Table 3). Concentrating on the patient group




Figure 1 Prognosis of ovarian cancer patients according to age. Kapla
elderly ovarian cancer patients regarding progression-free survival (PFS) (A;
months, p < 0.001). Statistical comparison by log rank test.status were independent prognostic factors regarding PFS
(ECOG ≥1 vs. 0 HR 2.64, p = 0.048; Table 4). Receiving
mono-chemotherapy instead of combination chemother-
apy was almost significantly related to worse outcome re-
garding OS (HR 2.80, p = 0.055; Table 4).
Discussion
In this European multicenter study aiming to identify
and verify clinical and molecular prognostic factors forn-Meier curves demonstrating significantly impaired prognosis for





Figure 2 Prognosis of ovarian cancer patients according to age. Kaplan-Meier curves regarding progression-free (PFS) and overall survival
(OS) separately analyzed for patients ≥70 years with suboptimal or optimal oncologic treatment opposed to patients younger than 70 years
(A; PFS: 11 months vs. 18 months vs. 20 months, p = 0.05; B; OS: 20 months vs. 31 months vs. 64 months, p < 0.001). Statistical comparison by
log rank test. optimal = complete tumor resection and platinum-based chemotherapy.
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spectively included resulting in a well characterized cohort
of patients treated in high-volume gynecologic oncology cen-
ters. In our study prognosis of patients ≥70 was significantly
impaired. This report demonstrates that patients aged ≥ 70
years do frequently not receive optimal multimodal therapy
despite treatment in specialized cancer centers, possibly con-
tributing to the observed impaired outcome.
Debulking surgery with the intent of complete tumor
resection is frequently feasible, even in advanced disease
stages [4]. However, cytoreduction of advanced disease
often requires radical surgical steps like bowel resection,
upper abdominal surgery or pelvic as well as para-aortic
lymphadenectomy. In this context, a major concern of
surgeons towards elderly patients is the fear of a higher
complication and mortality rate as revealed by a retro-
spective analysis from the Washington State Hospital in
2009 with rising complication rates for abdominal sur-
gery according to age (65–69 years, 14.6%; 70–74 years,16.1%; 75–79 years, 18.8%; 80–84 years, 19.9%; 85–89
years, 22.6%; p < 0.001) [14]. Validated selection criteria
regarding reasonable treatment decisions for elderly pa-
tients are currently not available. In a systematic review,
however, focusing on primary cytoreductive surgery for
advanced ovarian cancer, a 30-day-mortalitity rate be-
tween 0 and 5.9% with a median of 2.7% has been
reported by Gerestein et al. [15]. Although age-specific
information in the investigated studies were sparse, post-
operative mortality seemed to be slightly elevated in eld-
erly patients (5.4-11.7%) albeit still acceptable [15]. This
was recently confirmed by Thrall et al. with a 30-day
mortality rate of 5.6% for elective surgeries in elderly
ovarian cancer patients [16]. In a retrospective investiga-
tion from Maryland, mortality rates of elderly patients
were reported to be lower in high-volume departments
compared to departments with less than 20 cytoreductive
surgeries for ovarian cancer per year [17]. In the present
analysis no deaths were registered within the first 30
Table 3 Multivariate analysis of prognostic factors for the overall patient cohort
Progression-free survival Overall survival
HR 95% CI p value HR 95% CI p value
FIGO stage IV vs. II-IIIC 2.169 1.489 3.159 <0.001 1.730 1.135 2.635 0.011
Grading
G2 vs. G1 1.809 0.711 4.604 0.213 1.681 0.560 5.049 0.355
G3 vs. G1 1.835 0.742 4.535 0.189 1.823 0.638 5.214 0.262
Lymph-node status
N1 vs. N0 1.046 0.732 1.494 0.805 1.495 0.913 2.448 0.110
Nx vs. N0 1.455 0.949 2.231 0.085 2.018 1.125 3.619 0.018
Residual tumor (yes vs. no) 1.384 0.995 1.926 0.054 1.568 1.038 2.369 0.033
Peritoneal carcinomatosis (yes vs. no) 2.600 1.811 3.733 <0.001 2.528 1.538 4.153 <0.001
Histologic subtype
Serous vs. mucinous 0.852 0.170 2.915 0.630 0.386 0.090 1.658 0.201
Serous vs. other 0.833 0.531 1.305 0.766 0.735 0.432 1.253 0.258
Age (<70y vs. ≥70y) 1.226 0.853 1.761 0.272 1.836 1.207 2.794 0.005
ECOG
≥1 vs. 0 1.137 0.824 1.571 0.434 1.315 0.842 2.052 0.229
Unknown vs. 0 0.852 0.409 1.775 0.669 1.185 0.457 3.070 0.727
Detailed analysis of possible prognostic factors regarding their statistical significance and independence by cox regression model for the overall patient
cohort (n = 275).
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was only slightly elevated for elderly patients compared to
the younger patient group (0.4%). In addition, periopera-
tive complication rates in this analysis were comparable
with previous reports [18,19] and did not show significantTable 4 Multivariate analysis of prognostic factors for elderly
Progression-free s
HR 95% CI
FIGO stage IV vs. II-IIIC 2.790 1.007 6.90
Grading
G2 vs. G1 0.351 0.020 6.31
G3 vs. G1 2.023 0.144 28.4
Lymph-node status
N1 vs. N0 0.277 0.050 1.53
Nx vs. N0 0.177 0.023 1.36
Residual tumor (yes vs. no) 0.635 0.233 1.73
Peritoneal carcinomatosis (yes vs. no) 1.752 0.734 4.18
Histologic subtype
Serous vs. other 0.120 0.008 1.85
Chemotherapy
Mono vs. combination 0.924 0.334 2.55
ECOG
≥1 vs. 0 2.637 1.007 6.90
Unknown vs. 0 2.682 0.435 16.6
Detailed analysis of possible prognostic factors regarding their statistical significanc
and older (n = 47).differences between younger and elderly patients despite
significantly poorer performance status in the elderly
group. These results underline that in high volume depart-
ments with multidisciplinary treatment and distinct ex-
perience for ovarian cancer, higher age itself as well aspatients (≥70 years)
urvival Overall survival
p value HR 95% CI p value
5 0.048 2.083 0.792 5.480 0.137
2 0.478 2.440 0.139 42.786 0.542
37 0.601 5.165 0.368 72.453 0.223
2 0.141 0.191 0.260 1.404 0.104
2 0.096 0.176 0.018 1.744 0.138
4 0.376 0.919 0.321 2.634 0.876
3 0.207 0.563 0.612 3.317 0.490
5 0.129 0.073 0.005 0.995 0.050
2 0.878 2.800 0.978 8.012 0.055
5 0.048 1.819 0.651 5.081 0.254
70 0.287 2.697 0.405 17.943 0.305
e and independence by cox regression model for the cohort of patients age 70
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optimal surgical treatment from the patients.
Although intraoperative procedures were equally dis-
tributed between elderly and younger patients except for
adnectomy, hysterectomy as well as pelvic and para-
aortic lymphadenectomy, complete macroscopic tumor
resection was less frequently achieved in elderly patients.
In addition, elderly patients were more likely to receive
single-agent chemotherapy which was almost not ap-
plied to younger patients and showed a prognostic trend
for worse outcome regarding OS in elderly patients.
Consecutively, the rate of sub-optimal oncologic man-
agement was significantly higher in elderly patients al-
though a general feasibility of multimodal treatment has
been previously proven for these patients [20]. As rates
for complete macroscopic tumor resection exceed the
frequency of pelvic or para-aortic lymphadenectomy in
the elderly cohort, in some of these cases lymphadenec-
tomy was not performed to spare the elderly the mor-
bidity of the procedures themselves. So far, rationales to
hesitate applying radical surgical and systemic therapy to
elderly patients are a higher prevalence of co-morbidities
and a general lowered life expectancy [21]. This is aggra-
vated by the low level of evidence on specific treatment
strategies for elderly patients [21,22]. A meta-analysis of
randomized controlled studies by Hilpert et al. con-
cluded that the investigators’ intention to maintain treat-
ment of elderly patients within the study protocol
despite protocol-predefined options as dose reductions,
cycle delay or supportive therapy is limited [3]. Further-
more, elderly patients in our cohort more frequently
underwent interval debulking surgery after neodadjuvant
chemotherapy shown to be related with worse outcome
compared to primary debulking surgery in this non- ran-
domized OVCAD cohort [23].
All these observations might explain the fact that age
itself could not convincingly be confirmed as an inde-
pendent prognostic factor in the present analysis. Al-
though several previously published studies attributed
age to be independently related with unfavourable out-
come in elderly patients [5-7], a large retrospective ana-
lysis from Denmark described that the prognostic
significance diminished for patients receiving optimal
oncologic treatment [8]. This is in line with the present
analysis, in which only patients being treated in high-
volume departments with high standards of quality and
a long year experience were included. For the elderly co-
hort, ECOG performance status was prognostically sig-
nificant with a favorable prognosis for patients without
significant comorbidities compared to patients with im-
paired performance status (ECOG ≥1). This further un-
derlines that chronical age itself is not an ideal factor to
stratify patients. As demonstrated, health and perform-
ance status of the patients (indicating their ‘biologicalage’) should rather be considered by gynecologic oncolo-
gists before treatment decisions are made. Although
ECOG performance status as well as ASA (American So-
ciety for Anesthesiologists) scale reflecting co-morbidities
might roughly estimate the functional status of our pa-
tients, further, more thorough assessment strategies are
highly warranted. Within the international PACE study
(Preoperative Assessment of Cancer in the Elderly) a geri-
atric assessment tool for elderly cancer patients (>70
years) was prospectively evaluated and recently published
[24]. In this trial, different validated evaluation tests as the
Comprehensive Geriatric Assessment (CGA), the Brief Fa-
tigue Inventory and the ASA scale were combined to con-
ceive a reliable picture of the health, functional and
cognitive status of elderly patients [25]. This approach was
able to predict the risk of both postsurgical complications
and extended hospital stay and appears to be a helpful
additional tool for decision making [26]. However, predict-
ive accuracy of this approach needs to be further validated
in future studies.
Regarding the obvious underrepresentation of elderly
patients in current clinical trials, studies specifically con-
centrating on the distinct needs and expectations of eld-
erly patients are highly desirable [3,27]. These trials
should also consider that apart from effects on overall
survival, improved PFS would be the more important
therapeutic goal for elderly patients. As older patients
are more likely to die from other causes than cancer, po-
tential effects on overall survival might diminish [13].
Moreover, an improved PFS may lead to a better quality
of the remaining life which would otherwise be signifi-
cantly impaired by symptomatic advanced ovarian can-
cer. In general, specific trials for elderly and frail
patients might serve as ideal context to establish new
therapeutic endpoints like patient reported outcomes
(PRO) [28].
The Gynecologic Cancer Intergroup (GCIG) is cur-
rently planning a prospective trial specifically tailored
for elderly women with ovarian cancer (EWOC) that
evaluates optimal treatment strategies for elderly pa-
tients with the disease but will also address possible new
endpoints.
Conclusions
Elderly patients with ovarian cancer are often treated
less radically than younger patients which has been con-
firmed in this European multicenter study. Their out-
come is significantly impaired despite no consistent
prognostic effect of age.
Notwithstanding this treatment reality, age itself
should not be a reason to withhold optimal oncologic
treatment from elderly patients. Comprehensive pre-
operative assessment should be performed considering
the biological age and functional status of the patients.
Trillsch et al. Journal of Ovarian Research 2013, 6:42 Page 9 of 9
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be defined accounting for co-morbidities and expected
complications.
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